162 related articles for article (PubMed ID: 21865363)
1. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Ibáñez L; Diaz M; Sebastiani G; Sánchez-Infantes D; Salvador C; Lopez-Bermejo A; de Zegher F
J Clin Endocrinol Metab; 2011 Nov; 96(11):3361-6. PubMed ID: 21865363
[TBL] [Abstract][Full Text] [Related]
2. Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Díaz M; Chacón MR; López-Bermejo A; Maymó-Masip E; Salvador C; Vendrell J; de Zegher F; Ibáñez L
J Clin Endocrinol Metab; 2012 Oct; 97(10):3630-8. PubMed ID: 22791755
[TBL] [Abstract][Full Text] [Related]
3. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity.
Ibáñez L; Díaz M; Sebastiani G; Marcos MV; López-Bermejo A; de Zegher F
J Clin Endocrinol Metab; 2013 May; 98(5):E902-7. PubMed ID: 23547047
[TBL] [Abstract][Full Text] [Related]
4. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
5. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Ibáñez L; López-Bermejo A; del Rio L; Enríquez G; Valls C; de Zegher F
J Clin Endocrinol Metab; 2007 May; 92(5):1710-4. PubMed ID: 17299064
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Ibáñez L; López-Bermejo A; Díaz M; Enríquez G; Valls C; de Zegher F
Clin Endocrinol (Oxf); 2008 Feb; 68(2):317-20. PubMed ID: 18031315
[TBL] [Abstract][Full Text] [Related]
7. Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Díaz M; Gallego-Escuredo JM; de Zegher F; Villarroya F; Ibáñez L
Diabetes Metab; 2016 Jun; 42(3):196-9. PubMed ID: 26546387
[No Abstract] [Full Text] [Related]
8. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception.
Ibáñez L; De Zegher F
J Clin Endocrinol Metab; 2003 Oct; 88(10):4720-4. PubMed ID: 14557446
[TBL] [Abstract][Full Text] [Related]
9. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.
Ibáñez L; López-Bermejo A; Díaz M; Enríquez G; del Río L; de Zegher F
Clin Endocrinol (Oxf); 2009 Sep; 71(3):351-7. PubMed ID: 19018783
[TBL] [Abstract][Full Text] [Related]
10. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Ibáñez L; Ong K; Ferrer A; Amin R; Dunger D; de Zegher F
J Clin Endocrinol Metab; 2003 Jun; 88(6):2600-6. PubMed ID: 12788862
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of ethinylestradiol-drospirenone and flutamide-metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess.
Ibáñez L; Díaz M; López-Bermejo A; de Zegher F
Gynecol Endocrinol; 2011 Mar; 27(3):197-8. PubMed ID: 20528210
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Ibáñez L; Valls C; Ferrer A; Ong K; Dunger DB; De Zegher F
J Clin Endocrinol Metab; 2002 Jun; 87(6):2870-4. PubMed ID: 12050266
[TBL] [Abstract][Full Text] [Related]
13. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women.
Ibáñez L; de Zegher F
Fertil Steril; 2006 Jul; 86 Suppl 1():S24-5. PubMed ID: 16798281
[TBL] [Abstract][Full Text] [Related]
14. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome.
Karabulut A; Demirlenk S; Sevket O
Gynecol Endocrinol; 2012 Apr; 28(4):245-8. PubMed ID: 21961995
[TBL] [Abstract][Full Text] [Related]
15. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Ibáñez L; Valls C; Cabré S; De Zegher F
J Clin Endocrinol Metab; 2004 Sep; 89(9):4716-20. PubMed ID: 15356085
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide.
Ibáñez L; Potau N; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2000 Sep; 85(9):3251-5. PubMed ID: 10999817
[TBL] [Abstract][Full Text] [Related]
17. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women.
Ibáñez L; de Zegher F
Hum Reprod Update; 2006; 12(3):243-52. PubMed ID: 16407452
[TBL] [Abstract][Full Text] [Related]
18. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
[TBL] [Abstract][Full Text] [Related]
19. Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments.
Díaz M; de Zegher F; Ibáñez L
Front Endocrinol (Lausanne); 2023; 14():1125569. PubMed ID: 36843579
[TBL] [Abstract][Full Text] [Related]
20. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
